Donislecel

Donislecel
Clinical data
Trade namesLantidra
Other namesdonislecel-jujn
License data
Routes of
administration		Islet cell transplantation via intravenous infusion[1][2]
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes.[3][5] Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells. Donislecel is administered as a single infusion into the hepatic (liver) portal vein.[5]

The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.[5]

Donislecel was approved for medical use in the United States in June 2023.[3][5]

  1. ^ "Archived copy". Food and Drug Administration. Archived from the original on 9 December 2022. Retrieved 29 June 2023.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ "Archived copy". Food and Drug Administration. Archived from the original on 19 May 2021. Retrieved 29 June 2023.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ^ a b c "Lantidra- donislecel solution". DailyMed. 10 July 2023. Retrieved 28 August 2023.
  4. ^ "Lantidra". U.S. Food and Drug Administration (FDA). 28 June 2023. Archived from the original on 5 July 2023. Retrieved 5 July 2023.
  5. ^ a b c d e Cite error: The named reference FDA PR 20230628 was invoked but never defined (see the help page).